leadf
logo-loader
viewAcasti Pharma Inc

Full interview: Acasti Pharma 'marching to the goal-line' with two Phase 3 trials for its lead drug candidate CaPre

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) CSO & COO Pierre Lemieux tells Proactive the Québec-based company is 'marching to the goal-line' on two Phase 3 trials for its lead drug candidate, CaPre, with top-line results expected in December 2019 and January 2020, respectively.

Lemieux says the company's CEO, Jan D'Alvise will be presenting these expected milestone dates to investors at the Cantor Fitzgerald Global Healthcare Conference on October 2-4 in New York.

Quick facts: Acasti Pharma Inc

Price: 0.47 CAD

TSX-V:ACST
Market: TSX-V
Market Cap: $45.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Acasti Pharma eyes phase III success with double data readout towards year-end

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) CEO Jan D'Alvise speaks to Proactive's Andrew Scott after announcing their second Phase III trial for the drug CaPre has reached 100% randomisation - which means the last patient's been accepted into the trial and randomised either onto the drug or a...

on 4/6/19

2 min read